Barriers to HIV treatment among people who use injection drugs: Implications for 'treatment as prevention'

Current Opinion in HIV and AIDS

Volumn 7, Issue 4, 2012, Pages 332-338

  Milloy, Michael John ^a   Montaner, Julio ^a,b   Wood, Evan ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AIDS; antiretroviral therapy; HIV; injection drug use; prevention

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MORBIDITY; MORTALITY; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, INFECTIOUS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84862535125     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328354bcc8     Document Type: Review

References (79)

1. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-1028.
2. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372:1733-1745.
3. Kerr T, Tyndall M, Li K, et al. Safer injection facility use and syringe sharing in injection drug users [Internet]. Lancet 2005; 366:316-318. (Pubitemid 41019422)
4. Kerr T, Small W, Buchner C, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes [Internet]. Am J Public Health 2010; 100:1449-1453.
5. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990 [Internet]. AIDS 1994; 8:223-231. (Pubitemid 24094119)
6. Montaner JSG, Wood E, Kerr T, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes [Internet]. J Acquir Immune Defic Syndr 2010; 55:S5-S9.
7. Das M, Chu PL, Santos G-M, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5:e11068.
8. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Br Med J 2009; 338:b1649-b11649.
9. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
10. The Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
11. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies [Internet]. AIDS 2007; 21:1185-1197.
12. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [Internet]. N Engl J Med 1997; 337:734-739. (Pubitemid 27417972)
13. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
14. Porter K, Babiker A, Bhaskaran K, et al., CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART [Internet]. Lancet 2003; 362:1267-1274. (Pubitemid 37324254)
15. Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS ONE 2011; 6:e22698
16. Centers for Disease Control and Prevention (CDC). Vital signs: HIV prevention through care and treatment: United States. Morb Mortal Wkly Rep 2011; 60:1618-1623.
17. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4 cell count [Internet]. J Am Med Assoc 1998; 279:35-40. (Pubitemid 28070548)
18. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharm 2006; 1:280-295. (Pubitemid 44244133)
19. Baum MK, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users [Internet]. J Acquir Immune Defic Syndr 2009; 50:93-99.
20. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization [Internet]. J Acquir Immune Defic Syndr 2011; 56:146-150
21. Fairbairn N, Kerr T, Milloy M-J, et al. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Behav 2011; 36:762-763.
22. McGowan CC, Weinstein DD, Samenow CP, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS ONE 2011; 6:e18462.
23. Qian H-Z, Stinnette S, Rebeiro P, et al. The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat 2011; 41:14-20.
24. Wood E, Hogg RS, Yip B, et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy [Internet]. J Infect Dis 2003; 188:1421-1425. (Pubitemid 37523926)
25. Wood E, Montaner JSG, Tyndall MW, et al. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy [Internet]. J Infect Dis 2003; 188:1164-1170. (Pubitemid 37338981)
26. Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with nonadherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care 2011; 23:775-785.
27. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users [Internet]. J Am Med Assoc 2008; 300:550-554.
28. Kerr T, Marshall BDL, Milloy M-J, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend 2012. doi: 10.1016/j.drugalcdep.2011. 12.019.
29. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010; 376:367-387.
30. Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med 2010; 34:128-138.
31. Vogenthaler NS, Hadley C, Rodriguez AE, et al. Depressive symptoms and food insufficiency among HIV-infected crack users in Atlanta and Miami. AIDS Behav 2010; 15:1520-1526.
32. Walton G, Co SJ, Milloy M-J, et al. High prevalence of childhood emotional, physical and sexual trauma among a Canadian cohort of HIV-seropositive illicit drug users. AIDS Care 2011; 23:714-721.
33. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/ AIDS treatment nonadherence: a review and meta-analysis [Internet]. J Acquir Immune Defic Syndr 2011; 58:181-187.
34. D Volkow N, D Baler R, L Normand J. The unrealized potential of addiction science in curbing the HIVepidemic [Internet]. Curr HIVRes 2011; 9:393-395.
35. Amato L, Davoli M, Aperucci C, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and researC.H. J Subst Abuse Treat 2005; 28:321-329. (Pubitemid 40733141)
36. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103:1828-1836.
37. Uhlmann S, Milloy M-J, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010; 105:907-913.
38. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S22-S32.
39. Chaudhry AA, Botsko M, Weiss L, et al. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIVcare [Internet]. J Acquir ImmuneDefic Syndr2011;56(SUPPL. 1):S14-S21.
40. Egan JE, Netherland J, Gass J, et al. Patient perspectives on buprenorphine/ naloxone treatment in the context of HIV care [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S46-S53.
41. Korthuis PT, Tozzi MJ, Nandi V, et al. Improved quality of life for opioiddependent patients receiving buprenorphine treatment in HIV clinics [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S39-S45.
42. Korthuis PT, Fiellin DA, Fu R, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S83-S90.
43. Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al., BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/ naloxone in HIV-infected opioid-dependent patients [Internet] J Acquir Immune Defic Syndr 2011; 56(SUPPL. 1):S62-S67.
44. Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S68-S75.
45. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups [Internet]. Clin Infect Dis 2006; 42:1628-1635.
46. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 2009; 374:2064-2071.
47. Altice FL, Maru DSR, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007; 45:770-778. (Pubitemid 47378892)
48. Berg KM, Litwin A, Li X, et al. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend 2011; 113:192-199.
49. Babudieri S, Dorrucci M, Boschini A, et al. Targeting candidates for directly administered highly active antiretroviral therapy: benefits observed in HIVinfected injecting drug users in residential drug-rehabilitation facilities. AIDS Patient Care STDS 2011; 25:359-364.
50. Bell J, Trinh L, Butler B, et al. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104:1193-1200.
51. Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIVinfected opioid-dependent patients receiving buprenorphine/naloxone [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S33-S38.
52. Berg KM, Litwin AH, Li X, et al. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention [Internet]. Clin Infect Dis 2011; 53:936-943.
53. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroindependent individuals [Internet]. Cochrane Database Syst Rev 2011; 12:CD003410.
54. Sullivan LE, Botsko M, Cunningham CO, et al. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone [Internet]. J Acquir Immune Defic Syndr 2011; 56 (SUPPL. 1):S54-S61.
55. Malinowska K, Hoover J, Alexandrova A. Unintended consequences [Internet]. Open Society Institute; 2003.
56. Knowlton AR, Yang C, Bohnert A, et al. Informal care and reciprocity of support are associated with HAART adherence among men in Baltimore, MD, USA. AIDS Behav 2010; 15:1429-1436.
57. Korthuis PT, Saha S, Chander G, et al. Substance use and the quality of patient-provider communication in HIV clinics. AIDS Behav 2010; 15:832-841.
58. Lambers FAE, Stolte IG, van den Berg CHSB, et al. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam [Internet]. Int J Drug Policy 2011; 22:210-218.
59. Lehavot K, Huh D, Walters KL, et al. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence [Internet]. AIDS Patient Care STDS 2011; 25:181-189.
60. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis [Internet]. Health Psychol 2004; 23:207-218.
61. Johnson MO, Chesney MA, Goldstein RB, et al., NIMH Healthy Living Project Team. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: a mediation model. AIDS Patient Care STDS 2006; 20:258-268.
62. Clatts MC, Rodriguez-Diaz CE, Garcia H, et al. Preliminary evidence of significant gaps in continuity of HIV care among excarcerated populations in Puerto Rico. J Int Assoc Phys AIDS Care 2011; 10:339-341.
63. Milloy M.-J., Kerr T, Buxton J, et al. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2011. doi: 10.1097/ QAI.0b013e3182433288.
64. Milloy M-J, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 2011; 203:1215-1221.
65. Westergaard RP, Kirk GD, Richesson DR, et al. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis 2011; 53:725-731.
66. Youmans E, Burch J, Moran R, et al. Disease progression and characteristics of HIV-infected women with and without a history of criminal justice involvement. AIDS Behav 2011. doi: 10.1007/s10461-011-0057-1.
67. Flanigan TP, Beckwith CG. The intertwined epidemics of HIV infection, incarceration, and substance abuse: a call to action. J Infect Dis 2011; 203:1201-1203.
68. Springer S, Friedland G, Doros G, et al. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials 2007; 8:205-212. (Pubitemid 47327457)
69. Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison [Internet]. J Am Med Assoc 2009; 301:848-857.
70. Bachireddy C, Bazazi AR, Kavasery R, et al. Attitudes toward opioid substitution therapy and preincarceration HIV transmission behaviors among HIVinfected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend 2011; 116:151-157.
71. Khan MR, Epperson MW, Mateu-Gelabert P, et al. Incarceration, sex with an STI-or HIV-infected partner, and infection with an STI or HIV in Bushwick, Brooklyn, NY: a social network perspective [Internet]. Am J Public Health 2011; 101:1110-1117.
72. Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam. World Health Organization; 2009.
73. Torture and other cruel, inhuman or degrading treatment or punishment. United Nations; 2009.
74. Csete J, Kaplan K, Hayashi K, et al. Compulsory drug detention center experiences among a community-based sample of injection drug users in Bangkok, Thailand. BMC Int Health Human Rights 2011; 11:12.
75. Latimore AD, Rudolph A, German D, et al. Predictors of incident and recurrent participation in the sale or delivery of drugs for profit amongst young methamphetamine users in Chiang Mai Province, Thailand, 2005-2006. Int J Drug Policy 2011; 22:259-266.
76. Riley ED, Moore K, Sorensen JL, et al. Basic subsistence needs and overall health among human immunodeficiency virus-infected homeless and unstably housed women. Am J Epidemiol 2011; 174:515-522.
77. Tapp C, Milloy M-J, Kerr T, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis 2011; 11:86.
78. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, et al. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010; 376:551-563.
79. Wood E, Werb D, Kazatchkine M, et al. Vienna Declaration: a call for evidence-based drug policies. Lancet 2010; 376:310-312.